Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

Jerzy Leszek

Jerzy Leszek

Vice-director & Head of Alzheimer’s disease Laboratory Wroclaw Medical University Poland Poland

Suresh Kumar

Suresh Kumar

Neurologist Headache, TBI & Cognitive Research Institute U.S.A

Andres Barboza

Andres Barboza

Department of neurology Universidad del Aconcagua Argentina Argentina

Theodore A Petti

Theodore A Petti

Rutgers-Robert Wood Johnson Medical School USA

Ahmed Ammar

Ahmed Ammar

Dammam University Saudi Arabia

Ad Verheul

Ad Verheul

Centre De Hartenberg Netherlands


About Conference

On behalf of the” 17th International Conference on Alzheimers Disease & Dementia” which is scheduled to be held during December 06-07, 2023 at  Rome, Italy, we are honored to invite you to join us from any part of the world, to Dementia 2023. The conference program focuses on theme "Exploring Recent Advances and Diagnostic Approaches in Dementia and Alzheimer's Disease" {CME-CPD Credits Available}.

" Theme :  "Exploring Recent Advances and Diagnostic Approaches in Dementia and Alzheimer's Disease"

We Organizes 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Dementia 2023 offers a cutting edge program of Renowned International Speakers, attracting over 300+ experts in Demenia, Alzheimer’s Disease, Neurology. This conference intends to gather all the people across the globe like Students, Lecturers, Assistant Professors, Professors, Directors, Chairman, Chancellor, Scientists, Doctors, Managing Directors, Chief Executive Officers, Presidents and Noble Laureates and base a platform for them to share their experience, knowledge and research work, recent advancements in the field of  Neuroscience and dementia. In addition to cutting-edge presentations and debates, this year agenda provides you with an opportunity to participate in or organize a Workshop.

Brochure :  Click Here


Why to attend?

Dementia 2023 will congregate renowned speakers, principal investigators, experts, neurologist’s and Dementia researchers from both academia and health care industry will join together to discuss their views and research. The conference will be comprised of sessions by world class experts in the field of neurology. In  Dementia 2023, international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Dementia and Neurology. Why do attendees come to Dementia Conferences year after year through their professions? There are so many reasons. Here are the top few:

  • Direct interaction with our industry colleagues from around the world.
  • Play a role in mentoring the afterward generation of physician-scientists and academic leaders.
  • Bring home the latest up-to-dates on emerging technologies, clinical applications and practical solutions.
  • Estimate which products will be best for your organization as lots of exhibitors showcase their products and services.
  • Get the latest updates in technology and management of Dementia and neurology.

Target Audience:

  • Neurologists and Directors
  • Physicians
  • Neuroscientists
  • Specialists
  • researchers
  • Health care professionals
  • Professors
  • Industrial Experts
  • Neurosurgeons
  • Psychiatrist
  • Nutritional Scientists
  • Lecturers and Students from Academia in the study of Dementia
  • Students from Academia in the research of Neurology

Sessions/ Tracks

Track 1: Neurology

Neurology is the branch of medicine that deals with nervous system problems, which include both the central and peripheral nervous systems. The nervous system is a sophisticated and practical system that regulates and coordinates body actions. It is divided into two parts: the central nervous system and the peripheral nervous system, which include their coverings, blood vessels, and all effector tissue, such as muscle. A neurologist is a doctor who has specialized in neurology. Neurologists specialize in problems of the brain, spinal cord, and nerves.

Track 2: Dementia

Dementia is a term used to describe the symptoms of a variety of brain diseases. Alzheimer's disease is the most commonly recognized disorder, but other possibilities include brain disease. Early diagnosis aids in therapy, support, and design. Medications could help with some of the symptoms of insanity, but there is no permanent cure. The illness isn't typical for all elderly folks, as the majority of persons with insanity square measure older than 65. The prevalence of insanity rises with age, but it is not impossible for an elderly person to develop it. However, only one in every four patients with Alzheimer's disease or insanity has been diagnosed.

Track 3:Alzheimers Disease

Alzheimer's disease is the most prevalent cause of dementia in older persons, and it usually begins slowly and worsens with time. The most common early sign is trouble recalling recent events, sometimes known as short-term memory loss. By the end stage of Alzheimer's, the damage has spread and brain tissue has decreased significantly. Language problems, mood changes, loss of motivation, poorly managing self-care, and behavioural concerns can all occur as the condition progresses. Body functions deteriorate over time, eventually causing death.

Track 4: Neurodegenerative Diseases

Numerous bodily functions, including balance, mobility, speech, respiration, and heart function, are impacted by neurodegenerative diseases.  Many of these disorders are hereditary. Sometimes the cause is a medical problem such as alcoholism, a tumour, or a stroke. Toxins, chemicals, and viruses are possible culprits as well. Neurodegenerative diseases can be life-threatening. It all depends on the type. Most of them are incurable. Treatments may help alleviate symptoms, decrease discomfort, and boost mobility.

Neurodegenerative Diseases include:

  • Alzheimer's disease
  • Amyotrophic lateral sclerosis
  • Friedreich ataxia
  • Huntington's disease
  • Lewy body disease
  • Parkinson's disease·          

Track 5: Lewy Body Dementia

Lewy bodies are protein deposits that form in nerve cells in areas of the brain important in thinking, memory, and movement. The steady deterioration in mental ability caused by Lewy body dementia. Visual hallucinations and impairments in alertness and concentration are possible symptoms of Lewy body dementia. Parkinson's disease symptoms and side effects, for example, rigid muscles, slow development, and tremors, are among the various repercussions.

  • Neurotransmitter abnormalities
  • Advances in lewy body dementia research

Track 6: Aging and Dementia

Although some normal age-related changes in memory and thinking occur, disorientation and memory loss that interferes with daily life are not part of the normal aging process. Other signs of brain aging and dementia include the inability to complete tasks independently, difficulty naming items or close family members, forgetting the function of items, repeating questions, taking much longer to complete routine tasks, frequently misplacing items, inability to retrace steps, and becoming disoriented.

  • Neuro-anatomical changes in Ageing
  • Granulovacuolar Degeneration
  • Changes in Cerebral Cortical microvasculature
  • Advances of research in Ageing and Dementia

Track 7: Vascular Dementia

Vascular dementia is the second most common form of dementia after Alzheimer's disease. After Alzheimer's disease, vascular dementia is the most frequent type of dementia. It occurs when reduced blood flow affects brain tissue. Blood flow to brain tissue can be decreased or entirely blocked by a blood clot. Vascular dementia symptoms may appear gradually or after a stroke or significant surgery, such as heart bypass surgery or abdominal surgery.

Track 8:Addiction and Mental Health

Psychological well-being issues such as depression, anxiety, PTSD, and stress frequently lead to substance abuse, and using these drugs frequently devastates emotional well-being. When mental illness and substance abuse coexist, the condition is known as Dual Diagnosis or Co-Occurring Disorder. The following are the emotional well-being difficulties that are common with enslavement. Nervousness, Attention Deficit Hyperactivity Disorder, Post-Traumatic Stress Disorder, Eating Disorder, Bipolar Disorder, Schizophrenia, and Personality Disorders.

  • Alcohol addiction
  • Opioid dependence
  • Cognitive impairment
  • Drug use and toxicity
  • Hallucinogens abuse
  • Addiction and brain

Track 9: Child and Adolescent Psychiatry

Child and adolescent psychiatry is concerned with the diagnosis, treatment, and prevention of mental problems in both children and adults. The interdisciplinary channel disorder of emotion and behavior in child and adolescent psychiatry has its basis in neurophysiology, genetics, and environmental factors that affect the child's growth and development. Anxiety disorders, depression, and attention deficit hyperactivity disorder (ADHD) are the most frequent pediatric mental problems. Typically, children with mental disorders have worse educational achievement and high involvement in the criminal justice system. Several effective medications, educational or occupational interventions, as well as specific types of psychotherapy are available for treating child's mental disorders/mental illnesses. Each year, nearly one-fourth of children and teenagers experience some form of mental disorder.

Track 10: Psychiatry and Psychology

Psychiatry is a clinical specialty that diagnoses and treats intellectual problems, which are usually the ones that require treatment. Psyсhiаtrists аrе experienced сliniсаl mediсаl dосtоrs, they саn Ñ€rеsсribе mediсаtiоns, and they spend a lot of time with patients on mediсine control as а rоutinе оf trеаtmеnt. Begin by identifying the most common mental illnesses and how they differ from normalcy. syсhоlоgy is the study of behaviour and thoughts, including all aspects of awareness and sub-conscientious enjoyment as well as ideas.Psychologists focus intensely on psychotherapy and use behavioural interventions to treat patients who are experiencing emotional and mental distress.

Track 11: Neuroimaging Biomarkers

Neuroimaging biomarkers enable for an early diagnosis of Alzheimer's disease in the preclinical phases. Biomarker changes in patients with late-onset Alzheimer's disease, including results from investigations utilising MRI, advanced MRI techniques, positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Since neuroimaging biomarkers for neurological illnesses are difficult to detect, improved technology is allowing researchers to assess brain health for earlier diagnosis, faster medication development, and more effective therapies.

Track 12: Recent Studies & Case Reports

Dementia is defined as a progressive, irreversible decline in noesis that has an impact on a patient's pre-existing level of functioning. Alzheimer's disease is the most common etiology of the clinical condition of dementedness. Drug development in Alzheimer's disease is based on a growing pathophysiological hypothesis. Approaches to disease modification include the targeting of amyloid process, alphabetic character aggregation, endocrine signal, neuro-inflammation, and neurochemical pathology, with attempts to date yielding abandoned hopes and current promise. The amyloid cascade is crucial to various emerging pharmacological therapies, reflecting its dominance on the pathophysiological stage.

Track 13: Care, Practice, and Awareness

Persons with dementia have multiple psychological feature deficits, which include every memory impairment, which affects the flexibility to seek out new data or recall data previously learned, and one or more of the following symptoms-aphasia, apraxia, agnosia, or government dysfunction-such that the psychological feature deficits have a negative impact on social or activity functioning with a significant decline in previous abilities. As a result, creating caregiving methods for persons with dementia is critical, given the increasing frequency and the concomitant burden that dementia places not just on people, but also on carers, relatives, and the health-care system's resources. Standard perceptions of geriatric nursing offer a picture of care that is slower paced and less difficult than acute care. However, caring for the elderly, particularly those with dementia can be tough, unexpected, and unstable at times. This session covers medical professional education and coaching, care and quality of life, person-centered care, and psychological feature coaching, support and coaching for casual and skilled careers, putting knowledge domain into practise, non-pharmacological interventions, practical foods, and art, music, and life style.

Track 14: Alzheimer’s Disease Pathophysiology and Disease Mechanisms

Alzheimer's disease is a progressive dementia characterised by neuron loss and the presence of two major microscopic neuropathological hallmarks: living thing amyloid plaques and living thing neurofibrillary tangles. Early-onset Alzheimer's disease, a rare family form, is caused by a mutation in one of three genes: (amyloid precursor protein), (presenilin 2), or (presenilin 1). Noncontinuous type occurs most commonly after the age of sixty-five and accounts for many occurrences; it may be caused by a combination of hereditary and environmental factors. Amyloid plaques are mostly composed of the toxin amide amyloid which is broken sequentially from a larger precursor super molecule by two enzymes: -secretase (also known as BACE1) and -secretase.

Track 15: Brain Injury and Behavioral Neuroscience

Traumatic brain injury is a problem with numerous origins, pathologies, and tremendously variable and frequently multidimensional clinical manifestations. Because of its affinity for brain systems underlying cognitive and complex behavioural activities, it may induce chronic and severe psychiatric disorder that requires specialist management. Traumatic brain injury is common in various neuropsychiatric illnesses and may act as a breeding ground for novel ideas in neurodegenerative disease. 

Track 16: Neuropharmacology

The study of neuropharmacology focuses on how drugs change the way the nervous system works and the neural pathways in the brain that are involved in behaviour. Neuropharmacology is divided into two primary subfields: behavioural and molecular. Neuropsychopharmacology, which includes the study of how drug addiction and dependence affect the human brain, is the area of study that behavioural neuropharmacology primarily focuses on. The main objective of molecular neuropharmacology is to create medications that improve brain function by investigating neurons and their neurochemical connections.

Track 17: Recent Advancement in Treatments of Dementia

Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies are some of the disorders being studied. Dementia, as a generic word, refers to a variety of symptoms that impair memory, everyday functioning, and communication abilities. Alzheimer's disease progresses over time and affects memory and thinking.

  • Primary mental health care and nursing
  • Psychopharmacological treatment
  • Advanced drugs for dementia
  • Family therapy in nursing
  • Cognitive behavioral therapy

Track 18: Novel Therapeutic Targets and Mechanisms for Treatment

Alzheimer's disease is a progressive neurodegenerative disease characterised histopathologically by the presence of plaques made primarily of Abeta amyloid and tangles composed primarily of hyperphosphorylated alphabetic character. There is currently no medication that would reverse the sickness, and everyone in this medical specialty is focused on treating the symptoms of the illness. With numerous new drugs beginning clinical trials, Alzheimer's treatment is entering a fresh new and exciting phase. Several of these new medicines are based on our most recent understanding of the pathologic process of Alzheimer's and are intended to either reduce or stop the disease's progression. Therapies aimed at some aspect of beta-amyloid accumulation, neurofibrillary tangle creation, and the inflammatory response are all being considered, as are the difficulties associated with each space. It's still unclear whether any of those approaches are unbeatable, but the great amount of work in each of those three domains gives some hope that a successful Alzheimer's treatment is on the horizon.

  • Neuroendocrine Pharmacology
  • Neurotransmitter-based targets
  • Neurotrophic factors
  • Super molecule aggregation
  • Deep brain stimulation
  • Cistron medical care

YRF (Young Research Forum)

Dementia 2023's Prestigious Award for Young Researchers

The Dementia 2023 Committee is pleased to announce the "17th International Conference on Alzheimer's Disease & Dementia" which will take place on October 16-17, 2023 in Vancouver, Canada.

Dementia 2023 Young Scientist Awards:

The Dementia 2023 Committee intends to honour prestigious awards for talented Young researchers, scientists, Young Investigators, Post-Graduate students, Post-doctoral fellows, Trainees, and Junior faculty in recognition of their outstanding contribution to the conference theme. The Young Scientist Awards make every effort to provide early career academicians with a strong professional development opportunity by bringing together experts to exchange and share their experiences on all aspects of dementia and Alzheimer's disease.

Young Research Awards Dementia 2023 Nomination: Outstanding Masters/Ph.D./Post Doctorate Thesis Work Only 25 presentations are permitted at the Dementia 2023 young researchers forum.


  • Young Scientist Award recognition certificate and memento to the winners.
  • Our conferences provide the best platform for your research through oral presentations
  • Networking allows you to learn about career advancement using the most recent technologies.
  • This Forum will provide young scientists with relevant and timely information.
  • A platform for young researchers to collaborate for better development.
  • Allow for research interaction with established senior investigators from around the world.
  • Discuss your ideas with eminent researchers and mentors.
  • It is an incredible opportunity for young researchers to learn about research areas and broaden their research knowledge.


  • Young Investigators, Post-Graduate students, Post-doctoral fellows, Trainees, and Junior faculty with a minimum of 5 years of research experience
  • Presentation must be in scientific sessions of the conference.
  • 6 Each Young Scientist/Researcher can only submit one paper (as first author or co-author). Under 35 years old is the age limit.
  • All submissions must be submitted in English.

Market Analysis

Importance and Scope:

Dementia is a common neurodegenerative disease in which patients experience various behavioural changes, with primary symptoms such as a decline in memory or other thinking skills that can worsen as the condition progresses. It majorly affects people aged 65 years and above.

Global Dementia and Alzheimer's disease Treatment Market

The global market for dementia and Alzheimer's disease treatment is segmented by drug class, distribution channel, company, and region. The market is divided into three categories: cholinergic/cholinesterase inhibitors, memantine, and combination drugs.

The dementia and Alzheimer's disease market is dominated by cholinergic/cholinesterase inhibitors.The Dementia Alzheimer's disease market is expected to gain market growth from 2021 to 2028, growing at a CAGR of 10% during the forecast period.Dementia treatment is supportive and aims to alleviate symptoms as much as possible. According to Data Bridge Market Research, the Dementia treatment market will expand at an 8.50% CAGR from 2022 to 2029. Global Dementia Treatment Market, By Types, Drug Class, Therapy Type (Cognitive Stimulation Therapy, Cognitive Behavioral Therapy (CBT)), Route of Administration (Oral, Parenteral), End Users, Distribution Channel, Industry Trends and Forecast to 2029.


Global Dementia Drugs Market

The market for dementia medications was valued at $8.7 billion in 2021 and is projected to reach $19.7 billion by 2031, rising at an 8.5% CAGR between 2022 and 2031. A rise in the prevalence of Alzheimer's disease, improvements in R&D efforts for drug development, and a rise in the use of early diagnosis will all contribute to the global market for dementia medications expanding throughout the projected period. A number of factors contribute to the market's global expansion, including the rising geriatric population, increased R&D spending by players and the existence of promising pipeline candidates, increased spending on the construction of healthcare infrastructure, increased public awareness of disease prevention in developing countries, and a surge in demand for personalised medicine. 

Participation options and Benefits

Participation Options:

Dementia 2023 provides the participants with different modes or ways to participate as Delegate or Speaker under ACADEMIC / STUDENT / BUSINESS Category.

  • Keynote speaker: 35-40 minutes
  • Speaker (oral presentation): 25-30 minutes (only one person can present)
  • Speaker (workshop): 45-50 minutes (more than 1 can present)
  • Speaker (special session): 45-50 minutes (more than 1 can present)
  • Speaker (symposium): more than 45 minutes (more than 1 can present
  • Delegate (only registration): will have access to all the sessions with all the benefits of registration
  • Poster presenter:  can present a poster and enjoy the benefits of delegate
  • Remote attendance:  can participate via video presentation or e-poster presentation

Participation Benefits:

  • Attend Keynote Presentation by world’s most eminent researchers
  • Access to all the sessions
  • Get OCM certificate
  • Get worldwide acknowledgment to your profile and Research
  • Get your abstracts published with unique DOI in International Journals
  • Get up to 50% discounts for publishing your entire article in our open access International Journals
  • Get Handbooks and conference kits
  • Get an access to the network with eminent personalities from worldwide

Past Conference Report

Dementia 2022

We are thankful to all our wonderful Speakers, Conference Attendees, Students and Associations for making Dementia 2022  Conference the best ever!

16th International Conference on Alzheimers Disease & Dementia was held on October 19-20, 2022 Barcelona, Spain; based on the theme “Explicating Advancements to Combat the Silent Epidemic of Dementia and Alzheimer". Benevolent response and active participation was received from the Organizing Committee Members along with Scientists, Researchers, Students and leaders from various fields of Pediatrics, who made this event an outstanding success.

Conference Series LLC Ltd expresses its gratitude to all the participants who made this event grad success.

The meeting reflected various sessions, in which discussions were held on the following major scientific tracks:

  • Dementia
  • Dementia Lewy Body
  • Neurology
  • Neurological Disorders
  • Care Practice and Awareness
  • Ageing and Dementia
  • Dementia Nursing
  • Recent Studies & Case Reports
  • Alzheimer’s Disease
  • Alzheimer’s Clinical Trials and Studies
  • Molecular Genetics and Biology of Dementia
  • Novel Therapeutic Targets and Mechanisms for Treatment
  • Neurodegenerative Diseases
  • Psychiatry Mental health disorders
  • Animal Models and Translational Medicine

Conference Series LLC Ltd offers its heart felt appreciation to keynote speakers, dexterous of field, various outside experts, company representatives and is obliged to other eminent personalities who interweaved with the organisation and supported the conference in every aspect, without which the conference would not have been possible.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Dementia 2023, Conference Series LLC Ltd would like to announce the commencement of the “17th International Conference on Alzheimers Disease & Dementia” to be held in December 06-07, 2023 Rome, Italy. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Alzheimers Disease & Dementia.

Mark your calendars for the upcoming Conference; we are hoping to see you soon!

For More details visit:

Let us meet again @ Dementia 2023

Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date December 06-07, 2023

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

Journals of Alzheimers Disease and Parkinsonism Journal of Neurological Disorders Journal of Neurology and Neuroscience

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by


  • Acetylcholinesterase
  • Advances In Lewy Body Dementia Research
  • Advances Of Research In Ageing And Dementia
  • Age-related Macular Degeneration
  • Ageing And Dementia
  • Alzheimer Disease And Cellular Mechanisms
  • Alzheimers Clinical Trials And Studies
  • Alzheimers Clinical Trials And Studies
  • Alzheimers Disease
  • Alzheimers Disease
  • Alzheimers Disease Early Diagnosis And Symptoms
  • Alzheimers Disease Imaging
  • Alzheimers Illness
  • Alzheimers Sickness
  • Alzheimers, Barrier And Transport
  • Amnestic Mild Cognitive Impairment
  • Amyloid Beta
  • Amyloid Neuroimaging And Biomarkers
  • Amyloid Plaques And Neurofibrillary Tangles
  • Amyloid Protein In Alzheimer?s And Dementia
  • Apolipoprotein E
  • Attention
  • Brain Ageing
  • Brain Sciences
  • Care And Quality Of Life
  • Care Practice And Awareness
  • Central Auditory Processing
  • Cerebrum Aggregation Of Poisonous Amyloid
  • Changes In Cerebral Cortical Microvasculature
  • Cistron Medical Care
  • Clinical Features Of Dementia
  • Clinical Motor Evaluation
  • Clinical Studies Of Alzheimers
  • Clinical Trials
  • Coaching Of Medical Professionals
  • Cognitive Dysfunction
  • Cognitive Reserve
  • Concentration
  • Deep Brain Stimulation
  • Dementia
  • Dementia Lewy Body
  • Dementia Lewy Body
  • Dementia Nursing
  • Dementia Nursing Care Plan
  • Dementia Physiotherapy
  • Disease Mechanisms
  • Drug-delivery Systems
  • Emotional Intelligence
  • ER Stress
  • Eremostachys Labiosiformis
  • Fractal Dimension
  • Frontotemporal Dementia
  • Genetic
  • Genetic Risk For Alzheimers
  • Geriatric Nursing
  • Geriatrics
  • Granulovacuolar Degeneration
  • Huntingtons Disease (HD)
  • Image Grading
  • Late-onset Alzheimers Disease
  • Lipofuscin
  • Logopenic Primary Progressive Aphasia
  • Melatonin
  • Mental Health
  • Microglia
  • Mild Cognitive Impairment
  • Mitochondrial Pathology
  • Molecular Genetics And Biology Of Dementia
  • Molecular Genetics Of Frontotemporal Dementia
  • Molecular Genetics Of Neurodegenerative Dementias
  • Motor Abnormalities In Dementia
  • Motor Neurone Diseases (MND)
  • Multimorbidity
  • Music Therapy In Dementia
  • Neuro-anatomical Changes In Ageing
  • Neurochemical Pathology
  • Neurocognitive Testing
  • Neurodegenerative Dementias
  • Neurodegenerative Diseases
  • Neuroendocrine Pharmacology
  • Neurofibrillary
  • Neurogranin
  • Neuron
  • Neuroprotection
  • Neuropsychology
  • Neurotransmitter
  • Neurotransmitter Abnormalities
  • Neurotransmitter-based Targets
  • Neurotrophic Factors
  • Non-pharmacological Interventions
  • Other Dementias
  • Parkinsons Disease
  • Pathophysiology And Disease
  • PD-related Disorders
  • Peripheral Retina
  • Person Focused Care
  • Polyglutamine Diseases
  • Positron Emission Tomography
  • Posterior Cortical Atrophy
  • Primary Progressive Aphasia
  • Prion Disease
  • Psychiatric Symptoms
  • Psychiatry Mental Health Disorders
  • Psychometrics
  • Quality Of Life
  • Randomized Controlled Trials
  • Recent Studies & Case Reports
  • Resistance Exercise
  • Risk Factors Of Alzheimers
  • Salidroside
  • Social Engagement
  • Speech Processing
  • Speech Recognition
  • Spinocerebellar Ataxia (SCA)
  • Stroop Color-word Test
  • Super Molecule Aggregation
  • Synaptic Plasticity
  • Temporal Lobe
  • Therapeutic Interventions In Dementia
  • Therapeutic Targets And Mechanisms For Treatment